Nisa Investment Advisors LLC raised its position in shares of ImmunoGen, Inc. (NASDAQ:IMGN – Get Rating) by 116.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,390 shares of the biotechnology company’s stock after buying an additional 5,600 shares during the period. Nisa Investment Advisors LLC’s holdings in ImmunoGen were worth $47,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds and other institutional investors have also modified their holdings of the company. XTX Topco Ltd purchased a new position in shares of ImmunoGen during the first quarter worth $62,000. TFC Financial Management boosted its position in shares of ImmunoGen by 18.1% during the first quarter. TFC Financial Management now owns 17,950 shares of the biotechnology company’s stock worth $85,000 after buying an additional 2,750 shares during the period. Eqis Capital Management Inc. purchased a new position in shares of ImmunoGen during the first quarter worth $96,000. Kestra Advisory Services LLC boosted its position in shares of ImmunoGen by 14.6% during the first quarter. Kestra Advisory Services LLC now owns 23,468 shares of the biotechnology company’s stock worth $112,000 after buying an additional 2,985 shares during the period. Finally, Leo Brokerage LLC purchased a new position in shares of ImmunoGen during the first quarter worth $119,000. 95.58% of the stock is currently owned by hedge funds and other institutional investors.
ImmunoGen Stock Performance
IMGN opened at $5.35 on Thursday. The business’s 50-day simple moving average is $5.49 and its 200-day simple moving average is $4.95. ImmunoGen, Inc. has a one year low of $3.10 and a one year high of $7.77. The stock has a market capitalization of $1.18 billion, a P/E ratio of -6.52 and a beta of 1.06.
Analyst Ratings Changes
ImmunoGen, Inc, a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm.
- Get a free copy of the StockNews.com research report on ImmunoGen (IMGN)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.